Showing 21 - 40 results of 7,171 for search '(( 5 ((ppm decrease) OR (nn decrease)) ) OR ((( 50 ng decrease ) OR ( 50 we decrease ))))', query time: 0.43s Refine Results
  1. 21
  2. 22
  3. 23
  4. 24

    Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

    Published 2020
    “…<p><b>(a)</b> Autocorrelation profiles of 53 key BO-NN features. Per feature, a black line shows the time point where the autocorrelation drops below .5. …”
  5. 25

    ngLVA degradation kinetics. by Nicole A. Grieshaber (11175417)

    Published 2022
    “…<p>Cos-7 cell infected with L2-euoprom-ngLVA, treated with 34 μg/ml chloramphenicol (CAM) or vehicle only (1:1000 EtOH in RPMI) at 35 hpi (arrow). …”
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32

    Synthesis of polymers 5 and 6. by Ghadeer Mubarak (21567569)

    Published 2025
    “…The results showed that AMCs act as efficient corrosion inhibitors, with over 90% inhibition efficiency ( ) at 20 ppm concentration. The electrochemical investigation results indicated that the AMCs with hydrophilic and hydrophobic ratios of 100 (<b>5</b>), 90:10 (<b>6a</b>), and 80:20 (<b>6b</b>) manifest of 87.74%, 92.12%, and 93.53%, respectively. …”
  13. 33
  14. 34

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  15. 35

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40